CYP2B6 and cancer: Previously, we reported that stable expression of the pan-caspase inhibitor p35 in 9L gliosarcoma cells engineered to express CYP2B6 delayed, but did not prevent death of the P450-expressing tumor cells, thereby increasing overall CPA activation and cancer cell death [29].